伊諾妥珠單抗奧佐米星

{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 458271836
| type = mab
| image = Mab-ozogamicin.svg
| image_class = skin-invert-image
| alt =

| mab_type = mab
| source = zu/o
| target = CD22

| tradename = Besponsa
| Drugs.com =
| MedlinePlus = a617041
| DailyMedID = Inotuzumab ozogamicin
| pregnancy_AU = D
| pregnancy_category =
| routes_of_administration = 靜脈注射
| ATC_prefix = L01
| ATC_suffix = FB01

| legal_AU = S4
| legal_CA = Rx-only
| legal_CA_comment = /Schedule D
| legal_UK = POM
| legal_UK_comment = 。本藥需靜脈輸注給藥。

本藥由一株針對CD22的人類化抗體（伊諾妥珠單抗，）與屬於的細胞毒性小分子藥物（奧佐米星，）組成。

美国食品药品监督管理局將它視為（）。

參考文獻
外部連結
*
*